Secretory Leukocyte Protease Inhibitor (SLPI) promotes hepatic resolution responses in acute liver failure (ALF)

被引：0
|
作者：
Triantafyllou, Evangelos [1 ,2 ]
Pop, Oltin T. [1 ]
Liaskou, Evaggelia [3 ,4 ]
Bernsmeier, Christine [1 ]
Khamri, Wafa [2 ]
Stamataki, Zania [3 ,4 ]
Ma, Yun [1 ]
Thursz, Mark R. [2 ]
Wendon, Julia [1 ]
Quaglia, Alberto [1 ]
Weston, Chris J. [3 ,4 ]
Curbishley, Stuart M. [3 ,4 ]
Adams, David H. [3 ,4 ]
Antoniades, Charalambos G. [1 ,2 ]
机构：
[1] Kings Coll London, Inst Liver Studies, London WC2R 2LS, England
[2] Univ London Imperial Coll Sci Technol & Med, Sect Hepatol, London, England
[3] Univ Birmingham, NIHR Biomed Res Unit, Birmingham, W Midlands, England
[4] Univ Birmingham, Liver Res Ctr, Birmingham, W Midlands, England
来源：
HEPATOLOGY | 2014年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
741
引用
收藏
页码：560A / 560A
页数：1
相关论文
共 50 条
  • [31] Expression of Secretory Leukocyte Protease Inhibitor (SLPI) Detected by Immunohistochemistry in Hepatocellular and Cholangiocellular Tumours
    Ong, D. J.
    Hall, A.
    Triantafyllou, E.
    Pop, O.
    Thursz, M.
    Luong, T.
    Quaglia, A.
    JOURNAL OF PATHOLOGY, 2019, 249 : S45 - S45
  • [32] Anti-HIV activity of newly cloned secretory leukocyte protease inhibitor (SLPI)
    Konopka, K
    Shine, NR
    Wang, SC
    Düzgünes, N
    Whitman, CP
    ANTIVIRAL RESEARCH, 2003, 57 (03) : A47 - A47
  • [33] Identification of the secretory leukocyte protease inhibitor (SLPI) as a target of IRF-1 regulation
    Nguyen, H
    Teskey, L
    Lin, RT
    Hiscott, J
    ONCOGENE, 1999, 18 (39) : 5455 - 5463
  • [34] Temporal Induction of Secretory Leukocyte Protease Inhibitor (SLPI) in Odontoblasts by Lipopolysaccharide and Wound Infection
    Choi, Baik-Dong
    Jeong, Soon-Jeong
    Wang, Guanlin
    Kim, Heung-Joong
    Kim, Byung-Ock
    Hwang, Ho-Keel
    Lim, Do-Seun
    Kim, Sook-Hyang
    Jeong, Moon-Jin
    JOURNAL OF ENDODONTICS, 2009, 35 (07) : 997 - 1002
  • [35] Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome
    Dickey, Brittney L.
    Sirak, Bradley
    Martin-Gomez, Laura
    Reich, Richard R.
    Abrahamsen, Martha
    Isaacs-Soriano, Kimberly
    Chung, Christine H.
    Giuliano, Anna R.
    PLOS ONE, 2021, 16 (07):
  • [36] Secretory leukocyte protease inhibitor (SLPI) in cancer pathophysiology: Mechanisms of action and clinical implications
    Zhang, Xiaohua
    Liu, Shan Shan
    Ma, Jingru
    Qu, Wei
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 248
  • [37] Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its anti-protease function
    Yang, JX
    Zhu, J
    Sun, DX
    Ding, AH
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2005, 1745 (03): : 310 - 317
  • [38] Could targeting secretory leukocyte protease inhibitor be an effective therapeutic option to prevent infections in acute liver failure?
    Possamai, Lucia A.
    Khamri, Wafa
    Triantafyllou, Evangelos
    Wendon, Julia A.
    Thursz, Mark R.
    Antoniades, Charalambos G.
    IMMUNOTHERAPY, 2014, 6 (06) : 667 - 669
  • [39] Inhibition of secretory leukocyte protease inhibitor (SLPI) promotes the PUMA-mediated apoptosis and chemosensitivity to cisplatin in colorectal cancer cells
    Wei, Zhijiang
    Liu, Guiying
    Jia, Rufu
    Zhang, Wei
    Li, Li
    Zhang, Yuanyuan
    Wang, Zhijing
    Bai, Xiyong
    DISCOVER ONCOLOGY, 2023, 14 (01)
  • [40] Overexpression of secretory leukocyte protease inhibitor promotes the invasion of cholangiocarcinoma
    Jantra, Jeranan
    Kumphune, Sarawut
    Tohtong, Rutiwan
    Wongkham, Sopit
    Phimsen, Suchada
    CANCER SCIENCE, 2018, 109 : 1383 - 1383
12345